In 2016, the European Medicines Agency and the US Food and Drug Administration approved the use of ctDNA for EGFR testing, authorizing treatment of patients with metastatic NSCLC with osimertinib and erlotinib, respectively. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.